Business
Harrow Health Publishes First Quarter 2020 Letter to Stockholders
NASHVILLE, Tenn., May 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2020. Please click here to
About this update from Harrow, Inc.
[{"type":"text","content":"NASHVILLE, Tenn., May 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2020. Please click here to review Harrow Health’s Letter to Stockholders for the first quarter 2020.\n Mark L. Baum, CEO of Harrow Health, commented, “As we are starting to see segments of our economy begin to return to normal, I am excited to see the ImprimisRx team get back to what they do best - which is being a trusted provider to our physician customers, enabling them to help their patients, and improve health outcomes. While it is difficult to predict what the rest of 2020 will look like, we are starting to see orders come in as our customers re-open and we continue to be excited about Harrow’s upcoming events, catalysts, and developments in the near and long-term. All of these items, and more, are discussed in our Letter to Stockholders.” Conference Call and Webcast The company’s management team will host a question and answer conference call with analysts and an audio-only webcast today at 5:00 p.m. Eastern Daylight Time / 2:00 p.m. Pacific Daylight Time. To participate, please use the dial in or click on the link below: U.S. callers: (844) 602-0380International callers: (862) 298-0970Audio-only webcast: please click here Conference Call Replay A dial in replay of the call will be available until June 11, 2020. The webcast replay will be available until August 11, 2020. U.S. callers: (877) 481-4010, Replay ID: 34481International callers: (919) 882-2331, Replay ID: 34481Webcast: please click here About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals, Stowe Pharmaceuticals, Radley Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate webs...